Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Roctavian Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentHealthSpringPolicy RX501.128

    Valoctocogene roxaparvovec-rvox (Roctavian) Coverage Criteria

    Customize your policy alerts

    Sign up for healthspring Policy RX501.128 alerts

    Get alerted when Policy RX501.128 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity coverage for Roctavian (valoctocogene roxaparvovec-rvox), a gene therapy for adults with severe or moderately severe hemophilia A. Coverage is limited to members meeting all specified clinical, laboratory, infection, and treatment-history criteria; other indications and repeat treatment are considered unproven.

    Policy Summary
    PayerHealthSpring
    PolicyValoctocogene roxaparvovec-rvox (Roctavian) Coverage Criteria
    Policy CodePolicy RX501.128
    Change TypeNew policy
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionDocument that the member meets all 10 eligibility criteria before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10Required eligibility criteria
    18+Minimum age
    ≤1 IU/dLMaximum residual factor VIII
    ≥0.6 BUFVIII inhibitor screen threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1
    Lifetime treatment limit

    Coverage Criteria

    Initial Therapy Criteria

    Valoctocogene roxaparvovec-rvox (Roctavian) may be considered medically necessary when ALL of the following are met:

    Initial coverage criteria

    • Age and demographic criteria: The member is 18 years of age or older and was assigned male at birth.Age ≥18 years
    • Hemophilia severity: The member has severe or moderately severe hemophilia A, defined by residual factor VIII (FVIII) levels ≤1 IU/dL.Residual FVIII ≤1 IU/dL
    • Current treatment: The member is currently receiving FVIII prophylaxis.
    • FVIII inhibitor status: The member has no history of FVIII inhibitors and no positive screen result of ≥0.6 Bethesda units (BU) using the Nijmegen-Bethesda assay.Positive screen threshold ≥0.6 BU
    • AAV5 antibody status: There are no detectable pre-existing antibodies to the adeno-associated virus serotype 5 (AAV5) capsid.No detectable pre-existing AAV5 capsid antibodies
    • Liver assessment: A baseline liver health assessment has been performed, including but not limited to alanine transaminase (ALT).Baseline liver health assessment
    • Prior gene therapy: The member has no history of receiving gene therapy.
    • HIV status: The member is HIV negative or has controlled HIV infection.
    • Hepatitis status: The member has no active hepatitis B and/or hepatitis C infection.

    Valoctocogene roxaparvovec-rvox (Roctavian) is considered experimental, investigational, and/or unproven for all indications other than the policy-defined eligible population: adults meeting the specified criteria for severe or moderately severe hemophilia A.

    Repeat treatment with valoctocogene roxaparvovec-rvox (Roctavian) is considered experimental, investigational, and/or unproven.

    Coding and Clinical Thresholds

    HCPCS CodesHCPCS
    J1412
    Residual factor VIII level
    Threshold≤1 IU/dL
    MeasureResidual factor VIII (FVIII) level
    Policy useDefines the residual FVIII level for severe or moderately severe hemophilia A
    FVIII inhibitor positive screen
    Threshold≥0.6 Bethesda units (BU)
    AssayNijmegen-Bethesda assay
    ResultA positive FVIII inhibitor screen

    Documentation and Coverage Decision Risks

    Documentation Required

    Eligibility and Hemophilia Severity

    Document that the member is 18 years of age or older, was assigned male at birth, and has severe or moderately severe hemophilia A with residual FVIII levels ≤1 IU/dL.

    • Age: 18 years or older
    • Assigned male at birth
    • Severe or moderately severe hemophilia A with residual factor VIII (FVIII) ≤1 IU/dL
    Documentation Required

    FVIII Treatment and Inhibitor Status

    Document current FVIII prophylaxis and confirm no history of FVIII inhibitors or a positive Nijmegen-Bethesda assay screen result of ≥0.6 Bethesda units (BU).

    • Currently receiving FVIII prophylaxis
    • No history of FVIII inhibitors
    • No positive Nijmegen-Bethesda assay screen result ≥0.6 BU

    Policy Background

    This policy addresses Roctavian (valoctocogene roxaparvovec-rvox) for adults with severe or moderately severe hemophilia A. Coverage is limited to members who meet all specified eligibility requirements, including being 18 years of age or older, assigned male at birth, having residual FVIII levels of ≤1 IU/dL, and currently receiving FVIII prophylaxis. Required screening and clinical conditions include no history of FVIII inhibitors or a positive Nijmegen-Bethesda assay result of ≥0.6 Bethesda units, no detectable pre-existing AAV5 capsid antibodies, a baseline liver health assessment, no prior gene therapy, HIV-negative or controlled HIV status, and no active hepatitis B or hepatitis C infection. Other indications and repeat treatment are considered experimental, investigational, and/or unproven.

    Definitions

    Positive FVIII inhibitor screen
    DefinitionA laboratory result of at least 0.6 Bethesda units
    AssayNijmegen-Bethesda assay
    InterpretationPositive FVIII inhibitor screen
    Severe or moderately severe hemophilia A
    Factor VIII level≤1 IU/dL
    ConditionSevere or moderately severe hemophilia A
    Policy applicationUsed in this policy to define the eligible hemophilia A severity

    Initial Roctavian Therapy

    Initial Roctavian Treatment

    Initial treatment may be considered medically necessary when all policy criteria are met.

    Roctavian initial therapy

    • Age and demographic criteria: The member is 18 years of age or older and was assigned male at birth.Age ≥18 years
    • Hemophilia severity: The member has severe or moderately severe hemophilia A, defined by residual factor VIII (FVIII) levels ≤1 IU/dL.Residual FVIII ≤1 IU/dL
    • Current treatment: The member is currently receiving FVIII prophylaxis.

    Lifetime Quantity Limit

    Valoctocogene roxaparvovec-rvox
    Lifetime limit1 injection per lifetime
    DrugValoctocogene roxaparvovec-rvox
    Repeat treatmentA second injection is not allowed

    Administration Setting

    Note

    Administer as a single intravenous dose

    For hospital outpatient administration, note that Study 301 administered a single intravenous dose of valoctocogene roxaparvovec-rvox.

    Policy Summary
    PayerHealthSpring
    PolicyValoctocogene roxaparvovec-rvox (Roctavian) Coverage Criteria
    Policy CodePolicy RX501.128
    Change TypeNew policy
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionDocument that the member meets all 10 eligibility criteria before requesting coverage.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsDocumentation and Coverage Decision RisksPolicy BackgroundDefinitionsInitial Roctavian TherapyLifetime Quantity LimitAdministration Setting
    FDA-defined severe hemophilia A
    Factor VIII activity<1 IU/dL
    ConditionSevere hemophilia A
    Regulatory contextFDA-defined adult indication for congenital factor VIII deficiency
    Hemophilia A diagnostic factor activity
    Diagnostic thresholdFactor VIII activity <40% of normal
    Equivalent value<0.40 IU/mL
    DiagnosisHemophilia A
    Hemophilia B diagnostic factor activity
    Diagnostic thresholdFactor IX activity <40% of normal
    Factor measuredFIX activity
    DiagnosisHemophilia B
    Severe hemophilia A residual FVIII level
    Residual FVIII threshold≤1 IU/dL
    ConditionSevere hemophilia A
    Study contextStudy 301 enrolled adult males with severe hemophilia A at this residual FVIII level
    Study 301 treatment dose
    Dose6 × 10^13 vg/kg body weight
    RouteSingle intravenous dose
    StudyStudy 301
    Non-inferiority margin for ABR difference
    Non-inferiority margin3.5
    OutcomeDifference in annualized bleeding rate (ABR)
    AnalysisThe pre-specified non-inferiority margin was met
    Documentation Required

    AAV5 Antibody Testing

    Provide testing demonstrating no detectable pre-existing antibodies to the adeno-associated virus serotype 5 (AAV5) capsid.

    • AAV5 capsid antibody testing must show no detectable pre-existing antibodies
    Documentation Required

    Baseline Liver Assessment

    Provide a baseline liver health assessment before treatment, including alanine transaminase (ALT).

    • Baseline liver health assessment
    • Include ALT testing
    Documentation Required

    Treatment and Infection History

    Document treatment and infection history, including no prior gene therapy, HIV-negative status or controlled HIV infection, and no active hepatitis B and/or hepatitis C infection.

    • No history of receiving gene therapy
    • HIV negative or HIV infection controlled
    • No active hepatitis B and/or hepatitis C infection
    Denial Risk

    Failure to Meet Eligibility Criteria

    Coverage may be denied when any one of the 10 eligibility criteria is not met or is not adequately documented.

    • Age ≥18 years
    • Assigned male at birth
    • Severe or moderately severe hemophilia A with residual FVIII ≤1 IU/dL
    • Currently receiving FVIII prophylaxis
    • No history of FVIII inhibitors or Nijmegen-Bethesda screen result ≥0.6 BU
    • No detectable pre-existing AAV5 capsid antibodies
    • Baseline liver health assessment including ALT
    • No prior gene therapy
    • HIV negative or controlled HIV infection
    • No active hepatitis B and/or hepatitis C infection
    Denial Risk

    Other Indications

    Valoctocogene roxaparvovec-rvox (Roctavian) is considered experimental, investigational, and/or unproven for all other indications.

    • Coverage is not supported outside qualifying severe or moderately severe hemophilia A
    Denial Risk

    Repeat Treatment

    Repeat treatment with valoctocogene roxaparvovec-rvox (Roctavian) is considered experimental, investigational, and/or unproven.

    • Repeat Roctavian treatment is not supported
    Denial Risk

    Contraindications Present

    Do not administer when a contraindication is present, including active infection, significant hepatic fibrosis, cirrhosis, or known hypersensitivity to mannitol.

    • Active infection, either acute or uncontrolled chronic
    • Known significant hepatic fibrosis, stage 3 or 4
    • Cirrhosis
    • Known hypersensitivity to mannitol
    Billing Rule

    Lifetime Dose Limit Exceeded

    A second injection is not allowed because the dosing limit is one injection per lifetime.

    • Lifetime limit: 1 injection
    Mild hemophilia
    Factor activity5% to 40% of normal
    Bleeding contextBleeding is generally associated with surgery, dental extraction, or major injury
    Spontaneous bleedingRarely occurs spontaneously
    Moderate hemophilia
    Factor activity1% to 5% of normal
    Bleeding contextBleeding may occur after surgery, injury, or dental work
    Unprovoked bleedingBleeding may occur without a clear reason
    Severe hemophilia
    Factor activityBelow 1% of normal
    Joint and muscle bleedingFrequent bleeding into joints and sometimes muscles may occur
    Spontaneous bleedingBleeding can occur for no obvious reason
    Hemophilia A diagnosis
    Factor VIII thresholdBelow 40% of normal (<0.40 IU/mL)
    Genetic provisionIn some circumstances, a pathogenic variant in the F8 gene may establish the diagnosis when factor VIII activity is ≥40%
    Additional documentationA normal von Willebrand factor antigen should also be documented
    Hemophilia B diagnosis
    Factor IX thresholdBelow 40% of normal
    Genetic provisionIn some circumstances, a pathogenic variant in the F9 gene may establish the diagnosis when factor IX activity is ≥40%
    ConditionHemophilia B
    Valoctocogene roxaparvovec-rvox
    Therapy typeAdeno-associated virus serotype 5 (AAV5)-mediated gene therapy
    TransgeneFunctional copy encoding the B-domain-deleted SQ form of human coagulation factor VIII (hFVIII-SQ)
    Site of expressionThe transgene is expressed in the liver using a liver-specific promoter
    ABR
    AbbreviationABR
    MeaningAnnualized bleeding rate
    Study rolePrimary efficacy outcome in the described study
    AAV5
    AbbreviationAAV5
    Full termAdeno-associated virus serotype 5
    ApplicationAAV5 capsid is the vector component used in the therapy
    FVIII IU/dL
    AbbreviationFVIII IU/dL
    MeaningFactor VIII activity expressed in international units per deciliter
    FactorFactor VIII
    ABR
    AbbreviationABR
    MeaningAnnualized bleeding rate
    Unit of expressionBleeds per year
    IU
    AbbreviationIU
    MeaningInternational units
    Use in the policyUsed to express factor activity and bleeding-related study measures
  1. FVIII inhibitor status: The member has no history of FVIII inhibitors and no positive screen result of ≥0.6 Bethesda units (BU) using the Nijmegen-Bethesda assay.Positive screen threshold ≥0.6 BU
  2. AAV5 antibody status: There are no detectable pre-existing antibodies to the AAV5 capsid.No detectable pre-existing AAV5 capsid antibodies
  3. Liver assessment: A baseline liver health assessment has been performed, including but not limited to ALT.Baseline liver health assessment
  4. Prior gene therapy: The member has no history of receiving gene therapy.
  5. HIV status: The member is HIV negative or has controlled HIV infection.
  6. Hepatitis status: The member has no active hepatitis B and/or hepatitis C infection.